Shanghai Ruidao Medical Technology
Irreversible electroporation systems for non-thermal tumor ablation
About Shanghai Ruidao Medical Technology
Shanghai Ruidao Medical Technology Co., Ltd. is a medical device company established in September 2016, specializing in irreversible electroporation (IRE) technology for tumor treatment. The company's founder is Sun Zhu.
The core of Ruidao Medical's offering is its composite steep pulse treatment equipment, a form of non-thermal ablation technology sometimes referred to as NanoKnife. This technology applies high-voltage, ultra-short electrical pulses to the cell membranes of tumors, creating permanent nano-sized pores that lead to cell apoptosis without affecting surrounding healthy tissue structures like blood vessels and nerves. This method is a distinct alternative to traditional thermal ablation techniques such as radiofrequency, microwave, or cryoablation. The company's flagship product was the first domestically developed composite steep pulse treatment device approved for prostate cancer therapy. Following its initial product success, the company has expanded its focus to other applications, including benign prostatic hyperplasia, liver cancer, and pulsed-field ablation (PFA) for atrial fibrillation. In July 2022, its pulsed-field ablation device was granted entry into the National Medical Products Administration's (NMPA) special review process for innovative medical devices.
Ruidao Medical has established a comprehensive intelligent solution for focal prostate cancer therapy that integrates disease diagnosis, surgical planning, and energy ablation, which includes a prostate puncture navigation robot and a cloud data planning platform. The company has secured significant funding to advance its research, development, and clinical trials. In September 2021, it completed a Series A funding round of CNY 100 million (approximately $15.5 million) led by Detong Capital. This was followed by a Series A+ round in February 2023, raising over CNY 100 million, led by Paradise Silicon Valley and joined by Detong Capital and Qianzhan Capital.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2023 | $14M | $55M | Detong Capital · Qianshan Capital · Zhejiang Paradise Silicon Valley Asset Management Group | ↗ |
Growth signals
Latest recorded traffic for Shanghai Ruidao Medical Technology is 170 monthly website visits. Shanghai Ruidao Medical Technology's team grew 0% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Ruidao Medical Technology in its local ecosystem
The Shanghai Ruidao Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Detong Capital
Qianshan CapitalZhejiang Paradise Silicon Valley Asset Management Group
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Ruidao Medical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Ruidao Medical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.